Abstract. Ion channels are involved in regulating cell proliferation and apoptosis (programed cell death). Since increased cellular proliferation and inhibition of apoptosis are characteristic features of tumorigenesis, targeting ion channels is a promising strategy for treating cancer. CLC-3 is a member of the voltage-gated chloride channel superfamily and is expressed in many cancer cells. In the plasma membrane, CLC-3 functions as a chloride channel and is associated with cell proliferation and apoptosis. CLC-3 is also located in intracellular compartments, contributing to their acidity, which increases sequestration of drugs and leads to chemotherapy drug resistance. In this review, we summarize the recent findings concerning the involvement of CLC-3 in cancer and explore its potential in cancer therapy.
Introduction
Ion channels have various and important roles in cellular functions, ranging from the control of cell excitability to the regulation of cell volume. Channel dysfunctions have been associated with arrhythmias (1), skeletal muscle disorders (2) , neurological disorders including epilepsy and migration (3), cystic fibrosis (4) and endocrine disorders such as diabetes (5) . There is increasing evidence that ion channel dysfunction is also involved in cancer (6, 7) ; in particular, potassium, sodium, calcium and chloride channels have been shown to contribute to cancer development, metastasis and drug resistance (8, 9) . Targeting ion channels is a promising strategy for the treatment of cancer (10-12).
Recent studies have shown that ion channels and transporters have crucial roles in regulating cell proliferation, differentiation and apoptosis (13-16). The functions of ion channels include maintenance of membrane potential, cell cycle regulation and control of cell volume and thus contribute to the regulation of cellular processes (16) (17) (18) (19) . Cancer cells are characterized by the malignant transformation of cells resulting in increased proliferation, aberrant differentiation and reduced apoptosis. Although the mechanisms that control ion channels in cancer are not well understood, it is known that they contribute to cancer pathology by way of changes in the cell cycle and cell volume (6, 7, 13) .
Chloride channels contribute to the regulation of the cell cycle and volume (7, 11, 20) . The process of cell proliferation requires an increase in cell volume for generating daughter cells, while apoptosis is characterized by cell shrinkage (17). The volume-regulated anion channel (VRAC) is a major mechanism through which cells maintain a relatively constant cell volume (6) . The VRAC also participates in cell proliferation, differentiation, migration and apoptosis (21, 22) . Although the identity of the molecule responsible for VRAC-activated cellular swelling has not been established, the protein CLC-3 is a strong candidate (23). CLC-3 encodes a key component of the native VRAC in many cancer cells including that of prostate cancer epithelial, nasopharyngeal carcinoma and malignant glioma (24-26). Knockdown of CLC-3 inhibits endogenous VRAC currents in many cells such as cardiomyocytes, vascular smooth muscle cells and non-pigmented ciliary epithelial cells (27) (28) (29) . Inhibition of CLC-3 by specific anti-CLC9-3 antibodies reduces the swelling activated by chloride currents in human prostate cancer epithelial cells (25). Furthermore, CLC-3 mediates upregulation of VRAC by the anti-apoptotic b-cell lymphoma 2 (bCL2) protein (22, 25 Therefore, inhibition of CLC-3 is a potential strategy for increasing sensitivity to chemotherapy. In this review, we summarize the function of CLC-3 in cancer and discuss the mechanisms by which CLC-3 contributes to proliferation, apoptosis and drug resistance in cancer cells (Fig. 1) . we further explore whether CLC-3 may be a potential strategy for the treatment of cancer.
CLC-3 in cancer
Several studies have recently shown that CLC-3 participates in cell proliferation, apoptosis, the cell cycle and metastasis in many cancers. These include nasopharyngeal carcinoma, glioma, endometrial cancer and prostate cancer epithelial cells (25,39-43). here, we review the role of CLC-3 in the proliferation, apoptosis and drug resistance of these cancer cells ( Fig. 1 and Table I ).
Glioma. Glioma is a lethal brain tumor characterized by strong invasion into surrounding brain tissues (41,44). Glioma cell invasion requires cell volume changes that are regulated by many ion channels, including potassium channels and chloride channels (41). CLC-3 has been shown to have an important role in the invasiveness of human glioma cells (41,45). CLC-3 is abundantly expressed on the cytoplasmic membrane and in intracellular vesicles of glioma cells (26,41). Knockdown of CLC-3 reduces resting outwardly-rectifying chloride currents in glioma cells (41,46), suggesting that CLC-3 mediates resting chloride currents in the plasma membrane and thus may be involved in cell shrinkage during invasion.
The migration of glioma cells is associated with changes in the intracellular Ca 2+ concentration (47), and bradykinin has been shown to increase the intracellular Ca 2+ concentration via bradykinin b2 receptors and to induce cell migration along cerebral vasculature (48). Interestingly, CLC-3 can be activated by Ca 2+ /calmodulin-dependent kinase II (CAmKII) (49,50). Knockout of CLC-3 was found to reduce Ca 2+ -activated chloride currents mediated by CamKII in glioma cells and to decrease bradykinin-induced migration of human glioma cells (51).
CLC-3 also is implicated in premitotic condensation (PmC), a process that involves a decrease in cytoplasmic volume as glioma cells retract processes, round up and progress with mitosis (52). PmC is a crucial step in cell division and is linked to chromatic condensation (52). Knockout of CLC-3 by shRNA reduced PmC-associated outwardly rectifying chloride currents, inhibited the rate of PmC and impaired DNA condensation (26). Furthermore, similar to knockout of CLC-3 by shRNA, the chloride channel blocker 5-nitro-2-3-phenylpropylamino benzoic acid (NPPb) produces a similar effect on PmC, suggesting that the chloride channel function of CLC-3 on the plasma membrane determines the rate at which glioma cells undergo PmC and progress through mitosis (26). Furthermore, activation of CLC-3 by CamKII is involved in PmC and accelerates cytoplasmic condensation during glioma cell division (53), suggesting that CamKII-mediated activation of CLC-3 contributes to PmC.
Nasopharyngeal carcinoma. Nasopharyngeal carcinoma cells abundantly express CLC-3 (39,54-56). CLC-3 is located in the plasma membrane, cytoplasm and nuclei in nasopharyngeal carcinoma (CNE-2z) cells. under isotonic conditions, knockdown of CLC-3 was found to reduce background chloride currents and to inhibit ATP-induced chloride channels, accompanied by increased cell volume. These findings suggest that CLC-3 constitutes the major background chloride channel under isotonic conditions and may be responsible for maintenance of basal cell volume (56).
The role of CLC-3 in the regulation of cell volume is further supported by several studies showing that knockout of CLC-3 reduced volume-regulated chloride currents in CNE-2Z cells (39,40,57). In addition, CLC-3 was identified as the acid-activated chloride channel in CNE-2z cells, which can be inhibited by hypertonic solutions (42) and inhibition of the volume-activated chloride channel by CLC-3 knockout was found to be positively correlated with inhibition of cell proliferation and migration in CNE-2z cells (24,39). This suggests that CLC-3 is involved in cell proliferation and migration via modulation of volume-regulated chloride currents.
Prostate cancer. CLC-3 is expressed in lymph node carcinoma of prostate (LNCaP) cancer epithelial cells (25). Inhibition of CLC-3 by its specific antibodies effectively prevented activation of swelling-activated chloride currents in LNCaP cells. This suggests that CLC-3 may be the swelling-activated chloride channel in these cells. Furthermore, bCL2 increased the expression of CLC-3, accompanied by an increase in swelling-activated chloride currents, indicating that CLC-3 mediates bCL2-dependent modulation of swelling-activated chloride currents. It has been reported that bCL2 increases the ability of cells to regulate cell volume via upregulation of swelling-activated chloride currents in mDCK (madin-Darby canine kidney) cells (22). Since cell proliferation is associated with cell volume changes, CLC-3 is likely to contribute to cell volume changes during the proliferation of LNCaP cells.
Neuroendocrine tumors. CLC-3 has been found to be expressed in several neuroendocrine cell lines including bON (a human pancreatic neuroendocrine carcinoma), CC-18 (a human neuroendocrine-differentiated colonic carcinoma) and QGP-1 (a human pancreatic carcinoma of islet origin) (36). The expression of CLC-3 is predominantly located in the late endosome and lysosome, and overexpression of CLC-3 increases the acidity of intracellular vesicles. In addition, overexpression of CLC-3 decreased the cytotoxicity of the chemotherapeutic drug etoposide in human carcinoid bON cells. Since weakly basic chemotherapeutic drugs such as etoposide can be sequestered to acidic intracellular membrane compartments, the expression of CLC-3 may confer drug resistance to basic chemotherapeutic agents such as etoposide by increasing the acidity of intracellular compartments (58). (88, 89) due to inhibition of the PI3K/Akt/mTOR signaling pathway (89) . In addition, as a Cl -/h + transporter, CLC-3 contributes to the acidity of the late endosome and lysosomes, promoting sequestration of basic chemotherapeutic drugs and leading to drug resistance (35,37). CLC-3 inhibitors can be used for the treatment of cancer by inhibiting cell proliferation and preventing drug resistance, whereas CLC-3 activators exhibit antitumor activity through promotion of apoptosis. 
CLC-3 and VRACs in cell proliferation
Cancer cells are characterized by unlimited proliferation, which is associated with substantial changes in cell volume. During the early phase of cell proliferation, cells synthesize a large amount of proteins, which can result in intracellular hyperosmolarity, thus leading to water influx and cell swelling. Cancer cells maintain their normal size and avoid excessive cell volume changes that can damage structural integrity and cellular functions (59,60). Cell swelling initiates a regulatory volume decrease through activation of many ion channels (K + and Cl -) to return the cell volume to its normal size. The VRAC is important in the regulation of cell volume (61) and is associated with cell proliferation in various types of cells. These include hepatocytes (62), endothelial cells (63), pulmonary artery smooth muscle cells (64) and cancer cells (7, 65) .
The molecular characterization of the VRAC is still unclear. CLC-3 has been proposed as the native VRAC in various cells including cardiac myocytes, vascular smooth muscle cells and non-pigmented ciliary epithelial cells (27-29,66). Knockdown of CLC-3 by siRNA and anti-CLC-3 antibodies inhibits swelling-activated chloride currents, suggesting that CLC-3 is an integral component of the VRAC (27-29,66). however, the role of CLC-3 as a native VRAC remains controversial. Several other studies have shown that CLC-3 is predominantly expressed in intracellular compartments and is not the swelling-activated chloride channel (64, 61) . In addition, the swelling-activated chloride current remains present in CLC-3-knockout mice, arguing against the role of CLC-3 as a native VRAC (67) . however, since the properties of native swelling-activated chloride currents are altered in CLC-3-knockout mice, accompanied by the altered expression of many proteins (68) , it is possible that CLC-3 may be a regulatory component of the VRAC and another protein compensates for the loss of CLC-3 in these knockout mice. Furthermore, a recent study found that endogenous swelling-activated chloride currents are eliminated in inducible cardiac-specific CLC-3 knockout mice (70) , suggesting that CLC-3 may be a key component of VRAC in the heart. CLC-3 has been found in the plasma membrane and is involved in the regulation of cell volume in many types of cancers such as glioma, nasopharyngeal carcinoma and prostate cancer epithelial cells (25,39-41,57). Several lines of evidence have shown that CLC-3 has an important role in cell proliferation in vascular smooth muscle cells via control of the cell cycle (70, 71) . It has been reported that levels of CLC-3 vary according to the phase of the cell cycle in nasopharyngeal carcinoma cells, i.e. low in the G1 phase and high in the S phase (54). Furthermore, CLC-3 can promote passage of the cells through the G1 phase into the S (39). Suppression of CLC-3 was demonstrated to inhibit swelling-activated chloride currents and decrease regulatory volume, which was correlated with cell proliferation in nasopharyngeal carcinoma cells (39). Therefore, CLC-3 is believed to be involved in cell proliferation and cell cycle progression through regulation of cell volume via the swelling-activated chloride channel (39) (Fig. 1) .
Changes in cell volume was correlated with the regulation of cell cycle progression, which during proliferation is generally stimulated by cell swelling and inhibited by cell shrinkage (72, 73) . In addition, cell volume is greatest in the m phase and least in the G1 phase and increases in cell volume are associated with the G1-S transition (59). Although it is known that cell volume is associated with cell cycle progression, the regulatory mechanisms remain unclear. Recently, zhang et al (40) found that in nasopharyngeal carcinoma cells, CLC-3 is a downstream target of cyclin D1, which controls cell cycle progression through regulation of cyclin-dependent kinases (CDKs). Cyclin D1 promotes the protein expression of CLC-3, associated with an increase in volume-activated chloride channels, suggesting that cyclin D1 regulates volume-activated chloride currents via upregulation of CLC-3 expression. In addition, inhibition of CDK4 activated volume-activated chloride currents, whereas blockade of CDK6 reduced these currents (40). These results suggest that the cyclin D1-CDK4 complex may inhibit the VRAC and the cyclin D1-CDK6 complex may activate the VRAC. It appears that cyclin D1 can mediate cell cycle progression and regulate cell volume via CLC-3. Furthermore, it has been reported that cell swelling stimulates extracellular signal regulated kinase (ERK1/2) (59, 74, 75) , and ERK activity regulates the induction of cyclin D1 (76) (77) (78) . Therefore, it appears that cell volume regulates cell cycle progression via control of cyclin D1.
CLC-3 in cell apoptosis.
A characteristic hallmark of apoptosis is cell shrinkage or apoptotic volume decrease (AVD). AVD occurs early in apoptosis in response to apoptotic stimuli and may be a prerequisite (59,79). most commonly, subsequent to AVD is regulatory volume increase, which allows cells to return to their original cell volume (59). The VRAC has been shown to be involved in AVD (80) (81) (82) . CLC-3 has been found to contribute to the VRAC in prostate cancer epithelial cells and the anti-apoptotic bCL2 increases swelling-activated chloride currents via upregulation of CLC-3 expression (25). however, since inhibition of VRAC can effectively prevent apoptotic events (83) , the finding that bCL2 mediates upregulation of VRAC suggests that bCL2 promotes VRAC-mediated AVD and induces apoptosis. This clearly contradicts the anti-apoptotic function of bCL2. It is possible that CLC-3 may not contribute to the apoptosis-inducing VRAC. Consistent with this idea, Okada et al (84) concluded that CLC-3 is not the volume-sensitive outwardly rectifying chloride channel involved in AVD.
In basilar arterial smooth muscle cells, knockout of CLC-3 increases apoptosis induced by hydrogen peroxide via the intrinsic mitochondrial pathway (85) . In human bronchial epithelial cells, overexpression of CLC-3 inhibited transforming growth factor (TGF)-β 1-induced apoptosis, which was suppressed by overexpression of bCL2 (86) . Knockout of CLC-3 facilitated apoptosis induced by thapsigargin, a specific inhibitor of the endoplasmic reticulum calcium ATPase, in pheochromocytoma-derived PC12 cells (87) . These findings suggest that CLC-3 is likely to promote apoptosis in these cells via a different signaling pathway.
Accordingly, in nasopharyngeal carcinoma cells, the expression of CLC-3 was upregulated during early apoptosis and after treatment with paclitaxel. Overexpression of CLC-3 associated with microtubules was involved in paclitaxel-induced apoptosis (88) . Furthermore, in nasopharyngeal carcinoma cells activation of CLC-3 by a novel class of CLC-3 activators (bufadienolides) induced apoptosis via inhibition of the PI3K/Akt/mTOR signaling pathway (89) (Fig. 1) .
CLC-3 in drug resistance
multidrug resistance is the main obstacle in the treatment of cancer. Ion channels and transporters that are involved in promotion of cell proliferation and evasion of apoptosis contribute to the development of multidrug resistance (8,81). As discussed above, overexpression of CLC-3 is associated with increased cell proliferation. Thus, CLC-3 may be related to multidrug resistance in cancer cells via increased cell proliferation. Consistent with this idea, suppression of CLC-3 was found to increase the sensitivity of human glioma u251 cells to cisplatin via inhibition of Akt and autophagy (37).
CLC-3 is expressed in late endosomes and lysosomes and contributes to their acidity. Increasing the acidity of intracellular compartments confers drug resistance to weakly basic chemotherapeutic drugs. Therefore, overexpression of CLC-3 may increase sequestration of basic drugs in acidic compartments, thus leading to drug resistance (Fig. 1) . This hypothesis has been proven by the finding that overexpression of CLC-3 increases drug resistance to etoposide by increasing acidification of the late endocytic compartment in bON cells (36). Similarly, Xu et al (38) reported that in erythroleukemia K562 and RK562 cells, upregulation of CLC-3 by NPPB increased acidification of intracellular compartments and promoted sequestration of cisplatin, conferring drug resistance to cisplatin.
Targeting CLC-3 in the treatment of cancer
As described above, increased expression of CLC-3 in cancer cells stimulates proliferation and migration, but also increases apoptosis. It appears to be paradoxical that cancer cells can manage to upregulate CLC-3 to promote proliferation and migrate, while at the same time avoiding its pro-apoptotic effect. because the expression of CLC-3 is cell cycle-dependent (high in the S and low in the G1 phase) (39), transient upregulation of CLC-3 at specific stages between the G1 and S phases may promote cell cycle progression, leading to cancer cell proliferation. In contrast, persistent upregulation of CLC-3 may lead to apoptosis.
The mechanisms by which cancer cells evade apoptosis induced by upregulation of CLC-3 remain unclear. Since CLC-3 is regulated by anti-apoptotic bCL2 in prostate cancer cells (25) and bCL2 upregulation is required for the progression of prostate cancer cells (90) , it may be that cancer cells can upregulate anti-apoptotic proteins such as bCL2 to inhibit the pro-apoptotic effect of CLC-3.
CLC-3 is involved in cell proliferation and apoptosis and contributes to drug resistance in many cancer cells (Fig. 1) . CLC-3 inhibitors can be used for blocking cancer cell proliferation and increasing chemosensitivity, whereas CLC-3 activators can promote cancer cell apoptosis. Therefore, developing novel CLC-3 inhibitors and activators may be a strategy for the treatment of cancer (Table II) .
CLC-3 inhibitors.
A highly specific CLC-3 inhibitor is preferred for use in cancer therapy, to reduce nonspecific side effects. Unfortunately, specific CLC-3 inhibitors have not been developed. Several chloride channel inhibitors such as tamoxifen and NPPb have been shown to inhibit CLC-3 currents and reduce proliferation of many cancer cells (42, 56, 57, 65, 89) . However, these inhibitors are not specific for CLC-3. They can block other chloride channels such as Ca 2+ -activated chloride channel anoctamin 1 (also known as transmembrane member 16A or TmEm16A) (91) and therefore are not used as specific CLC-3 blockers. As far as cancer therapy is concerned, these inhibitors are not suitable to use because chloride channel inhibition is wide-ranging. Developing specific compounds for a chloride channel such as CLC-3 remains a major challenge.
Specific CLC-3 targeting can be affected by developing CLC-3-specific antibodies. Several studies have shown that CLC-3 antibodies can effectively inhibit CLC-3 currents (27, 68, 92) . It has been reported that antibodies against human Eag1 potassium channels display antitumor activity both in vitro and in vivo (93) . however, it remains to be determined whether antibodies against CLC-3 can be used for the treatment of cancer.
Specific inhibition of CLC-3 can be obtained by knockdown of CLC-3 with siRNAs. Knockdown of CLC-3 by specific siRNA has been used in many in vitro studies and effectively inhibits CLC-3 currents and CLC-3-mediated proliferation and apoptosis (41, 42, 46, 56, 57, 89) . however, the use of siRNA in cancer therapy has not been tested in animals or clinical studies.
Chlorotoxin, a 36-amino acid peptide that is isolated from a scorpion toxin, was originally regarded as a chloride channel inhibitor (94) . Chlorotoxin targets glioma cells specifically by binding to matrix metalloproteinase-2 (mmP-2) (95). A recent study by Qin et al (96) confirmed that mmP-2 mediates the target delivery from chlorotoxin-modified liposomes to tumors. This study also indicated that chlorotoxin inhibited CLC-3 chloride currents by binding with mmP-2, resulting in inhibition of cell migration in gliomas (96) and suggested that chlorotoxin may also target other cancers with high mmP-2 expression. A phase I clinical trial of a synthetic chlorotoxin derivative labelled with iodine-131 was completed with adult patients with recurrent high-grade glioma and a single dose of this compound was well tolerated (97) .
CLC-3 activator.
Recently, bufadienolides were discovered to be CLC-3 activators with antitumor activities (89) . Of the 7 compounds tested, bufalin exhibited the most potent antitumor activity and induced the largest chloride currents, which were blocked by CLC-3 siRNA. Furthermore, bufalin induced apoptosis via inhibition of the PI3K/Akt/mTOR signaling pathway. Knockout of CLC-3 reduced bufalin-induced apoptosis. These findings suggest that bufalin exerts its antitumor activity via activation of CLC-3 chloride currents, leading to inhibition of the PI3K/Akt/mTOR signaling pathway.
In addition, it has been reported that bufadienolides are associated with antitumor activity through various other mechanisms, including p21-dependent cell cycle arrest, induction of mitochondria-dependent and death receptor-mediated apoptosis and inhibition of anti-apoptotic proteins such as bCL2 (98) . It remains to be determined whether CLC-3 is involved in these antitumor mechanisms affected by bufadienolides. however, bufadienolides may not be safe to use, due to high toxicity (99, 100) . A recent study showed that bufadienolides in poloxamer-modified liposomes improved antitumor efficacy and reduced toxicity (101) and these may provide a safe way to deliver bufadienolides for the treatment of cancer.
Conclusions and perspectives
CLC-3 participates in the process of proliferation, apoptosis and drug resistance in many types of cancers, including nasopharyngeal carcinoma, glioma, endometrial cancer and prostate cancer epithelial cells (25,39-43). whether CLC-3 is the native VRAC is debatable, but CLC-3 has been found to be a component of the VRAC in many cancer cells. Inhibition of CLC-3 currents by channel blockers, CLC-3 antibodies and CLC-3 siRNA can effectively reduce cancer cell proliferation. Furthermore, CLC-3 contributes to the acidity of intracellular compartments, in which basic chemotherapeutic drugs can be sequestered, with subsequent chemoresistance. Inhibition of CLC3 can increase the sensitivity of cancer cells to chemotherapeutic drugs. In addition, CLC-3 contributes to the apoptosis of cancer cells and CLC-3 activators can promote this. Taken together, targeting CLC-3 could be a therapeutic strategy for the treatment of cancer.
There are many challenges to overcome before CLC-3 can be used in the treatment of cancer. Although CLC-3 currents have been associated with proliferation and apoptosis (39,88,89), the specific signaling pathway responsible for this is unclear. It is also essential that the different roles of CLC-3 in apoptosis and proliferation should be elucidated -it remains to be determined whether a specific CLC-3 activator that promotes cell apoptosis increases cell proliferation, thus leading to increased tumor growth, migration and invasion and whether a specific CLC-3 blocker that inhibits cell proliferation could reduce cell apoptosis. There is also very little knowledge regarding the expression of CLC-3 in tumor tissues of either animal models or cancer patients or the role of CLC-3 at different stages of cancer development. Finally, highly specific blockers and activators for CLC-3 are not available.
A major obstacle in implementing anti-CLC-3 therapy is that targeting CLC-3 may inhibit the normal functions of CLC-3 in non-cancer tissues. It is known that CLC-3 is widely expressed in many tissues, including the brain, and mice with disrupted CLC-3 exhibit signs of neurodegeneration (67, 102) . This problem needs to be solved before CLC-3 inhibitors can be used in the treatment of cancer. Further research into the mechanisms of CLC-3 in carcinogenesis may result in the development of novel drugs targeting CLC-3, which could serve as therapeutic tools in the treatment of cancer. 
